Verruca — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for verruca. 10 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
10
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Verruca

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating verruca. Each bar = one year. Y-axis scaled to peak year (7 patents).

7
29
3
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Aldara
IMIQUIMOD
 Bausch Health 10 73 — 2029-08-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11850245 Aldara method of use 81 2030-04-30
11318130 Aldara method of use 76 2029-12-11
11202752 Aldara method of use 76 2030-04-30
8598196 Aldara method of use 73 2029-08-18
8236816 Aldara method of use 73 2029-12-11
8222270 Aldara method of use 73 2029-12-11
8299109 Aldara method of use 73 2029-12-11
10238645 Aldara method of use 68 2029-08-18
10238644 Aldara method of use 68 2029-12-11
10918635 Aldara method of use 68 2030-04-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10918635 Aldara method of use 68 2030-04-30
10238644 Aldara method of use 68 2029-12-11
10238645 Aldara method of use 68 2029-08-18
8236816 Aldara method of use 73 2029-12-11
8222270 Aldara method of use 73 2029-12-11
8299109 Aldara method of use 73 2029-12-11
8598196 Aldara method of use 73 2029-08-18
11202752 Aldara method of use 76 2030-04-30
11318130 Aldara method of use 76 2029-12-11
11850245 Aldara method of use 81 2030-04-30

Related